Cure8 research brief
The study suggests a specific probiotic strain (Lactobacillus helveticus H9) reduced inflammation and colitis signs in a rat model and altered gut microbiota and metabolites, which may point to mechanisms worth testing in human research.
Researchers (microbiome and IBD), clinicians following probiotic research, and patients interested in microbiome-targeted therapies
This is a preclinical (rat) study using DSS to induce colitis, not a human clinical trial. The paper reports lower disease activity scores, reduced spleen weight, less colonic tissue damage, and lower serum TNF-α and IL-1β after L. helveticus H9 treatment, plus changes in the fecal metabolome and gut microbiota composition.
Because the work is in rats, it cannot be taken as proof that the same probiotic effects will occur in people with Crohn's disease or ulcerative colitis. Human studies would be needed to test safety, effective dosing, and clinical benefit.
This is an animal (DSS-induced colitis in rats) study reported in the journal Fermentation; results are preclinical and require human trials before they can inform patient care.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Scientific Research Foundation for High-level Talents of Huangshan University, award 2024xkjq017; Major Project of Anhui Provincial Collaborative Technology Service Center for Rural Revitali-zation, award XCZXZD2502; National Natural Science Foundation of China, award 32001711; award 32001711
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests L‑proline can reduce colitis in a mouse model and reshapes the gut microbiome, raising the possibility that amino-acid–based dietary strategies might influence intestinal inflammation through...
This preclinical study suggests cyanidin-3-O-glucoside (a dietary anthocyanin) can reduce inflammation and modify gut microbes and metabolites in an experimental colitis model by inhibiting NF-κB signaling. It points to...
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
